4 [6] E. Akdogˇan, M. So¨nmez, M. Yilmaz, A. Durmus¸, E. Ovali, and S. B. Omay, “The development of chronic myelogenous leukemia in a patient with malign ﬁbrous histiositom treated with radiotherapy: case report,” UHOD—Uluslararasi Hem- atoloji-Onkoloji Dergisi, vol. 18, no. 2, pp. 116–120, 2008. [7] D. Ozatli, A. Timuragaoglu, G. Alanoglu, S. Dizlek, and N. Uysalgil, “BCR-ABL transcript level and neutrophil alkaline phosphatase activity in CML patients treated with imatinib,” UHOD—Uluslararasi Hematoloji-Onkoloji Dergisi, vol. 20, no. 3, pp. 163–168, 2010. [8] E. Koca, M. Halil, Z. Adibelli et al., “Management of chronic myeloid leykemia (CML) in the pre-imatinib and imatinib era,” HAEMA, vol. 9, no. 5, pp. 663–671, 2006. [9] Y. Beyazit, M. Kekilli, and I. C. Haznedaroglu, “Second-gen- eration BCR-ABL kinase inhibitors in CML,” The New England Journal of Medicine, vol. 363, no. 17, p. 1673, 2010. [10] G. Saydam, I. C. Haznedaroglu, Y. Temiz et al., “Retrospective evaluation of patients treated with dasatinib for Philadel- phia positive leukemias: Turkish experience of 16 months,” UHOD—Uluslararasi Hematoloji-Onkoloji Dergisi, vol. 19, no. 4, pp. 195–204, 2009. [11] H. Kantarjian, S. O’Brien, M. Talpaz et al., “Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure,” Can- cer, vol. 109, no. 8, pp. 1556–1560, 2007. [12] M. Puttini, A. M. L. Coluccia, F. Boschelli et al., “In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells,” Cancer Research, vol. 66, no. 23, pp. 11314–11322, 2006. [13] J. M. Golas, K. Arndt, C. Etienne et al., “SKI-606, a 4-an- ilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice,” Cancer Research, vol. 63, no. 2, pp. 375–381, 2003. [14] L. L. Remsing Rix, U. Rix, J. Colinge et al., “Global target proﬁle of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells,” Leukemia, vol. 23, no. 3, pp. 477–485, 2009. [15] O. Bektas, I. C. Haznedaroglu, Y. Buyukasik et al., “Dasatinib- induced tumor lysis syndrome and following hematologic re- mission in ﬁbrotic blastic crisis of CML,” UHOD—Ulus- lararasi Hematoloji-Onkoloji Dergisi, vol. 20, no. 2, pp. 13–16, 2010. [16] G. Kaygusuz, I. Kuzu, E. Akpinar, and A. Uysal, “Extramed- ullary hematopoiesis in the axillary lymph node in a patient with an accelerated phase of chronic myeloid leukemia,” Turk- ish Journal of Hematology, vol. 26, no. 1, pp. 40–41, 2009. [17] S. G. O’Brien, F. Guilhot, R. A. Larson et al., “Imatinib com- pared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia,” The New England Journal of Medicine, vol. 348, no. 11, pp. 994–1004, 2003. [18] H. Kantarjian, N. P. Shah, A. Hochhaus et al., “Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia,” The New England Journal of Medicine, vol. 362, no. 24, pp. 2260–2270, 2010. [19] G. Saglio, D. W. Kim, S. Issaragrisil et al., “Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia,” The New England Journal of Medicine, vol. 362, no. 24, pp. 2251– 2259, 2010. Case Reports in Hematology [20] M. Baccarani, J. Cortes, F. Pane et al., “Chronic myeloid leukemia: an update of concepts and management recom- mendations of European LeukemiaNet,” Journal of Clinical Oncology, vol. 27, no. 35, pp. 6041–6051, 2009. [21] M. Talpaz, N. P. Shah, H. Kantarjian et al., “Dasatinib in imatinib-resistant Philadelphia chromosome-positive leu- kemias,” The New England Journal of Medicine, vol. 354, no. 24, pp. 2531–2541, 2006. [22] I. C. Haznedaroglu, E. Koca, S. Aksu et al., “The gray-zone concept, suboptimal response to imatinib, shall be removed from the ELN-CML recommendations,” UHOD—Uluslara- rasi Hematoloji-Onkoloji Dergisi, vol. 20, no. 2, pp. 25–26, 2010. [23] M. Baccarani, G. Rosti, F. Castagnetti et al., “Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study,” Blood, vol. 113, no. 19, pp. 4497–4504, 2009. [24] H. Kantarjian and J. Cortes, “Considerations in the man- agement of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy,” Journal of Clinical Oncology, vol. 29, no. 12, pp. 1512– 1516, 2011. [25] D. Jones, D. Thomas, C. C. Yin et al., “Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors,” Cancer, vol. 113, no. 5, pp. 985–994, 2008. [26] N. Velev, J. Cortes, R. Champlin et al., “Stem cell transplan- tation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I,” Cancer, vol. 116, no. 15, pp. 3631–3637, 2010. [27] Y. Buyukasik, “Use of second generation tyrosine kinase inhib- itors for second-line treatment of chronic myeloid leukemia after imatinib failure,” UHOD—Uluslararasi Hematoloji-Onk- oloji Dergisi, vol. 21, no. 2, supplement 1, pp. 4–9, 2011. [28] A. S. Yavuz, “Long-term treatment of chronic myeloid leu- kemia,” UHOD—Uluslararasi Hematoloji-Onkoloji Dergisi, vol. 21, no. 2, supplement 1, pp. 10–17, 2011. [29] Z. Gulbas, “Advanced-phase CML treatment and transplan- tation,” Uhod-UHOD—Uluslararasi Hematoloji-Onkoloji Der- gisi, vol. 21, no. 2, supplement, pp. 18–23, 2011. [30] F. Demirkan, “Current problems in the management of chron- ic myeloid leukemia in Turkey,” UHOD—Uluslararasi Hem- atoloji-Onkoloji Dergisi, vol. 21, no. 2, supplement 1, pp. 24– 28, 2011. [31] I. C. Haznedaroglu, M. Cetiner, and O. Ilhan, “The manage- ment of chronic myeloid leukemia in the era of second gen- eration tyrosine kinase inhibitors,” UHOD—Uluslararasi Hematoloji-Onkoloji Dergisi, vol. 21, no. 2, supplement 1, pp. 1–3, 2011.